Abstract:Abstract Introduction Burn units acknowledge the challenges of burn-site infection including risk to graft survival and IL-6 mediated systemic inflammatory response, sepsis, concurrent multiple organ failure and death. The risk of repeated grafts, additional ICU time and mortality correlates highly with Pseudomonas spp infection. This risk is compounded by high levels of AMR species (up to 50%) in burns units. The mortality and economic burden are significant and likely to worsen without innovation as AMR becomes increasingly prevalent. Methods A novel drug, based on an endogenous immunomodulatory compound (a physiologic aqueous chlorine with the acronym PAC) has been shown to possess broad anti-IL6, anti-microbial and keratinocyte activation activity. In vitro studies confirm efficacy against pathogens including AMR species. The compound is not an antibiotic and is termed compound-PAC. Over a 50 month period, a tertiary burns unit undertook a proof of concept, open label trial to assess the impact of the compound on survival in patients with confirmed Gram -ve bacterial infections in patient with >15% TBSA. Patients with Gram -ve infection entered the study arm of the trial. Aqueous compound-PAC was administered topically via both hydrotherapy showers and soaked dressings, on a 4-6 hourly basis. In the control arm, showering was performed with normal sterile saline at every dressing change. Data recorded age, gender, depth of burn + TBSA affected, confirmed Pseudomonas infection, length of stay, and overall survival. Results Results from audit analysis (blinded to treatment) revealed compound-PAC could be used to manage confirmed Gram -ve infection of burn-sites; clearing colonization of the wounds without adverse effect and maintaining this with continued use. Such treatment was also effective against other bacterial pathogens. Comparison of survival data of patients with confirmed infection treated with compound-PAC (n = 46) against patients without infection and not receiving this treatment (n= 94), revealed that study arm treatment statistically significantly improved survival compared with normal gold standard of recommended clinical care HR = 0.459 (95% CI 0.282 – 0.750 – P< 0.002). In addition, in patients with >50% TBSA, the use of compound-PAC doubled survival vs. control treatment. Conclusions Odds ratio analysis concluded patients receiving the study compound had 5x increased probability of survival vs the current standard of care. Applicability of Research to Practice The compound has ability to integrate into standard of care as a wash-drench, with potential survival, wound-healing and health-economic benefits. Further, potential, benefit may be the reduction on failure of skin grafts with reduced requirement for surgeries. A separate investigation is exploring the potential for use in treating inhalation burns.

A Multicenter Clinical Trial of Piperacillin/tazobactam in Burn Infection

Effect of Piperacillin/tazobactam on Treating Traumatic Brain Injury with Pulmonary Infection: a Clinical Observation

A Multicenter Clinical Trial on the Efficacy and Safety of Piperacillin/tazobactam for the Treatment of Patients with Hospital Acquired Pneumonia: Treatment of Hospital Acquired Pneumonia Forum in Huadong Area.

Analysis of efficacy and safety of panipenem/betamipron in treatment of 30 patients with severe bacterial infection

Multicenter Clinical Study on Piperacillin/Sulbactam for Treatment of Respiratory and Urinary Tract Infection

A Randomized Controlled Clinical Trial of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Bacterial Infections

Epidemiological Investigation of Burn Patients with Klebsiella Pneumoniae Infection and the Analysis of Risk Factors for Sepsis in Them

Clinical evaluation of piperacillin/tazobactam

[The Isolation of Pseudomonas Aeruginosa from Burn Wound and the Analysis of Its Antibiotic Resistant Spectrum].

Pathogen Distribution and Drug Resistance in A Burn Ward: A Three-Year Retrospective Analysis of A Single Center in China

Clinical Outcome and Antimicrobial Therapeutic Drug Monitoring for the Treatment of Infections in Acute Burn Patients

717 Survival Benefit with a Topical Anti-inflammatory with Antimicrobial Properties in Patients with >15%; TBSA Burns

Piperacillin/tazobactam in Treatment of Severe Craniocerebral Injury Complicated Pulmonary Infection: a Clinical Study

Epidemiology and Early Bacteriology of Extremely Severe Burns from an LPG Tanker Explosion in Eastern China

Pharmacoeconomics on Treatment of Gram-Negative Bacteria Infections with Cefoperazone-Sulbactam, Imipenem-Cilastatin, and Piperacillin-Tazobactam

Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients

A combination regimen of meropenem, cefoperazone‐sulbactam and minocycline for extensive burns with pan‐drug resistant Acinetobacter baumannii infection

Antibiotic prophylaxis with piperacillin–tazobactam reduces organ/space surgical site infection after pancreaticoduodenectomy: a retrospective and propensity score-matched analysis

Local Application of Probiotic Bacteria Prophylaxes against Sepsis and Death Resulting from Burn Wound Infection

Piperacillin/tazobactam for surgical prophylaxis during pancreatoduodenectomy: meta-analysis

[Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase]